GeneDx Q3 2026 adjusted net income falls 47% year-over-year to $8.6 million
Bitget2026/11/09 21:37- GeneDx’s third-quarter 2026 adjusted net income fell 47% year-over-year to $8.6 million.
- Revenue rose 5% year-over-year to $123.1 million; exome and genome revenue increased 12% to $110.4 million.
- Exome and genome test result volume climbed 25% year-over-year to 32,134.
- Expanded its genome testing portfolio with long-read whole genome sequencing and launched an online offering to broaden pediatric exome testing access.
- Maintained 2026 revenue guidance at $475–$490 million while lowering exome and genome revenue growth guidance to at least 17%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
